S&P Futures
3,925.00 +25.50 (+0.65%) Dow Futures
31,367.00 +154.00 (+0.49%) Nasdaq Futures
11,942.75 +102.00 (+0.86%) Russell 2000 Futures
1,785.10 +12.90 (+0.73%) Crude Oil
110.73 +0.45 (+0.41%) Gold
1,850.90 +8.80 (+0.48%)
Otonomy, Inc. (OTIC)
Chart Events
Performance Outlook
| Previous Close | 1.9400 |
| Open | 1.9600 |
| Bid | 1.5900 x 1300 |
| Ask | 1.8900 x 1200 |
| Day's Range | 1.8000 - 1.9800 |
| 52 Week Range | 1.1400 - 2.5900 |
| Volume | |
| Avg. Volume | 159,601 |
| Market Cap | 104.736M |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7800 |
| Earnings Date | Aug 02, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for OTIC
Related Research
- Otonomy, Inc.Technical Assessment: Bearish in the Intermediate-TermFollowing April's miserable performance, May isn't shaping up much better, at least so far. The S&P 500 took a 9% drubbing into April, and 14 trading days into the new month the index is off another (almost) 6%. Since its closing peak on January 3 at 4,796.56, the "500" made a minor new low on Thursday and is down 896 points (or 18.7)%. The Nasdaq has declined 29% from its November 2021 closing high, while the Nasdaq 100 is off 28%.RatingFair ValueEconomic Moat3 days agoArgus Research
- GlobeNewswire
Otonomy to Participate in the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright Global Investment Conference (Hybrid Conference). A pre-recorded company presentation by the Otonomy management team will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on May 24, 2022. A link to the presentation will also become available a
- GlobeNewswire
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of preclinical data for OTO-825 at the upcoming American Society of Gene & Cell Therapy (ASGCT) Meeting being held May 16-19 in Washington, DC. Dr. Phillip Uribe from Otonomy will be making a podium presentation entitled “Preclinical Development of an AAV-based Gene Therapy (OTO-825) for Con
- Motley Fool
Otonomy (OTIC) Q1 2022 Earnings Call Transcript
Joining me on the call from Otonomy are Dr. David Weber, president and chief executive officer; and Paul Cayer, chief financial and business officer. Before I turn the call over to Dr. Weber, I would like to remind you that today's call will include forward-looking statements based on current expectations.
